Elevation Oncology (ELEV)
(Delayed Data from NSDQ)
$0.54 USD
+0.02 (3.40%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.54 0.00 (0.30%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Elevation Oncology, Inc. (ELEV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.00 | $10.00 | $6.00 | 1,438.46% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Elevation Oncology, Inc. comes to $8.00. The forecasts range from a low of $6.00 to a high of $10.00. The average price target represents an increase of 1% from the last closing price of $0.52.
Analyst Price Targets (6 )
Broker Rating
Elevation Oncology, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, seven are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
8/6/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
6/28/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
5/31/2024 | Piper Sandler | Biren Amin | Not Available | Strong Buy |
5/14/2024 | Stephens | Sudan Loganathan | Not Available | Strong Buy |
5/3/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 7 |
Average Target Price | $8.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -0.20 |
ELEV FAQs
Elevation Oncology, Inc. (ELEV) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Elevation Oncology, Inc. (ELEV) is $8.00. The current on short-term price targets is based on 5 reports.
The forecasts for Elevation Oncology, Inc. (ELEV) range from a low of $6 to a high of $10. The average price target represents a increase of $1381.48 from the last closing price of $.54.
The current UPSIDE for Elevation Oncology, Inc. (ELEV) is 1381.48%
Based on short-term price targets offered by six analysts, the average price target for Elevation Oncology, Inc. comes to $8.00. The forecasts range from a low of $6.00 to a high of $10.00. The average price target represents an increase of 1% from the last closing price of $0.52.